

Ygal Haupt

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/442673/publications.pdf](https://exaly.com/author-pdf/442673/publications.pdf)

Version: 2024-02-01

92
papers

11,851
citations

56860

44
h-index

35719

98
g-index

122
all docs

122
docs citations

122
times ranked

16144
citing authors

#	ARTICLE	IF	CITATIONS
1	Mdm2 promotes the rapid degradation of p53. <i>Nature</i> , 1997, 387, 296-299.	36.2	4,094
2	Apoptosis - the p53 network. <i>Journal of Cell Science</i> , 2003, 116, 4077-4085.	2.1	1,013
3	The cellular response to p53: the decision between life and death. <i>Oncogene</i> , 1999, 18, 6145-6157.	5.9	542
4	Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E1/4-myc transgenic mice. <i>Cell</i> , 1991, 65, 753-763.	27.8	525
5	c-Jun and p53 Activity Is Modulated by SUMO-1 Modification. <i>Journal of Biological Chemistry</i> , 2000, 275, 13321-13329.	3.5	354
6	Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis. <i>Redox Biology</i> , 2018, 14, 100-115.	9.1	294
7	Clinical Overview of MDM2/X-Targeted Therapies. <i>Frontiers in Oncology</i> , 2016, 6, 7.	2.9	272
8	MDM4 is a key therapeutic target in cutaneous melanoma. <i>Nature Medicine</i> , 2012, 18, 1239-1247.	30.1	270
9	A functional p53-responsive intronic promoter is contained within the humanmdm2gene. <i>Nucleic Acids Research</i> , 1995, 23, 2584-2592.	14.0	269
10	Inhibiting the system xC [±] /glutathione axis selectively targets cancers with mutant-p53 accumulation. <i>Nature Communications</i> , 2017, 8, 14844.	13.2	242
11	Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. <i>Oncogene</i> , 1999, 18, 3205-3212.	5.9	190
12	Tumour suppression by p53: the importance of apoptosis and cellular senescence. <i>Journal of Pathology</i> , 2009, 219, 3-15.	4.5	164
13	Sex disparities matter in cancer development and therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 393-407.	28.8	162
14	Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. <i>EMBO Journal</i> , 2002, 21, 3715-3727.	8.2	161
15	The Mdm2 Oncoprotein Interacts with the Cell Fate Regulator Numb. <i>Molecular and Cellular Biology</i> , 1998, 18, 3974-3982.	2.5	135
16	Increasing Intracellular Bioavailable Copper Selectively Targets Prostate Cancer Cells. <i>ACS Chemical Biology</i> , 2013, 8, 1621-1631.	3.6	125
17	The Promyelocytic Leukemia Protein Protects p53 from Mdm2-mediated Inhibition and Degradation. <i>Journal of Biological Chemistry</i> , 2003, 278, 33134-33141.	3.5	123
18	Transactivation-deficient p73 ^Δ (p73 ^Δ exon2) inhibits apoptosis and competes with p53. <i>Oncogene</i> , 2001, 20, 514-522.	5.9	117

#	ARTICLE	IF	CITATIONS
19	Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. <i>Nature Communications</i> , 2015, 6, 7389.	13.2	108
20	MDM2 and Fbw7 cooperate to induce p63 protein degradation following DNA damage and cell differentiation. <i>Journal of Cell Science</i> , 2010, 123, 2423-2433.	2.1	105
21	WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. <i>Cancer Research</i> , 2015, 75, 5143-5154.	0.9	94
22	c-Abl Neutralizes the Inhibitory Effect of Mdm2 on p53. <i>Journal of Biological Chemistry</i> , 1999, 274, 8371-8374.	3.5	89
23	c-Abl Regulates p53 Levels under Normal and Stress Conditions by Preventing Its Nuclear Export and Ubiquitination. <i>Molecular and Cellular Biology</i> , 2001, 21, 5869-5878.	2.5	88
24	APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. <i>Gut</i> , 2015, 64, 1506-1516.	13.7	88
25	Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17990-18000.	7.6	85
26	Regulation of Mutant p53 Protein Expression. <i>Frontiers in Oncology</i> , 2015, 5, 284.	2.9	73
27	Role of p53 in the progression of gastric cancer. <i>Oncotarget</i> , 2014, 5, 12016-12026.	2.1	69
28	Mutations in Proline 82 of p53 Impair Its Activation by Pin1 and Chk2 in Response to DNA Damage. <i>Molecular and Cellular Biology</i> , 2005, 25, 5380-5388.	2.5	66
29	P53: A Guardian of Immunity Becomes Its Saboteur through Mutation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3452.	4.2	62
30	c-Abl Phosphorylates Hdmx and Regulates Its Interaction with p53. <i>Journal of Biological Chemistry</i> , 2009, 284, 4031-4039.	3.5	60
31	Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. <i>Nature Communications</i> , 2019, 10, 5385.	13.2	59
32	HPV16 E6 augments Wnt signaling in an E6AP-dependent manner. <i>Virology</i> , 2010, 396, 47-58.	2.5	57
33	The role of MDM2 and MDM4 in breast cancer development and prevention. <i>Journal of Molecular Cell Biology</i> , 2017, 9, 53-61.	3.3	57
34	C-Abl as a modulator of p53. <i>Biochemical and Biophysical Research Communications</i> , 2005, 331, 737-749.	2.2	56
35	High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. , 2020, 8, e000792.		56
36	Mdm2 in growth signaling and cancer. <i>Growth Factors</i> , 2005, 23, 183-192.	1.7	53

#	ARTICLE	IF	CITATIONS
37	The long and the short of it: the MDM4 tail so far. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 231-244.	3.3	53
38	p73 and p63: Why Do We Still Need Them?. <i>Cell Cycle</i> , 2004, 3, 884-892.	2.8	52
39	Clioquinol induces cytoplasmic clearance of the X-linked inhibitor of apoptosis protein (XIAP): therapeutic indication for prostate cancer. <i>Biochemical Journal</i> , 2011, 436, 481-491.	3.8	51
40	E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. <i>Blood</i> , 2012, 120, 822-832.	1.4	51
41	Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways. <i>Frontiers in Oncology</i> , 2016, 6, 12.	2.9	50
42	A Role for the Polyproline Domain of p53 in Its Regulation by Mdm2. <i>Journal of Biological Chemistry</i> , 2001, 276, 3785-3790.	3.5	47
43	The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. <i>Cancer Research</i> , 2016, 76, 4236-4248.	0.9	45
44	MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 87.	5.1	44
45	Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33ING1 in T.Tn human esophageal carcinoma cells. <i>Oncogene</i> , 2002, 21, 1208-1216.	5.9	43
46	Loss of p53 Causes Stochastic Aberrant X-Chromosome Inactivation and Female-Specific Neural Tube Defects. <i>Cell Reports</i> , 2019, 27, 442-454.e5.	6.3	41
47	Importance of p53 for cancer onset and therapy. <i>Anti-Cancer Drugs</i> , 2006, 17, 725-732.	1.4	36
48	Manipulation of the tumor suppressor p53 for potentiating cancer therapy. <i>Seminars in Cancer Biology</i> , 2004, 14, 244-252.	9.8	34
49	P53 licensed to kill? Operating the assassin. <i>Journal of Cellular Biochemistry</i> , 2003, 88, 76-82.	2.6	33
50	<scp>MDM4</scp> is a rational target for treating breast cancers with mutant p53. <i>Journal of Pathology</i> , 2017, 241, 661-670.	4.5	32
51	TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival. <i>Cancers</i> , 2020, 12, 1535.	3.8	32
52	The p53-Mdm2 Loop: A Critical Juncture of Stress Response. <i>Sub-Cellular Biochemistry</i> , 2014, 85, 161-186.	0.0	31
53	HPV16 E6 and E6AP differentially cooperate to stimulate or augment Wnt signaling. <i>Virology</i> , 2014, 468-470, 510-523.	2.5	29
54	SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1858-1867.	3.7	27

#	ARTICLE	IF	CITATIONS
55	E6AP promotes prostate cancer by reducing p27 expression. <i>Oncotarget</i> , 2017, 8, 42939-42948.	2.1	25
56	c-Abl Phosphorylates E6AP and Regulates Its E3 Ubiquitin Ligase Activity. <i>Biochemistry</i> , 2013, 52, 3119-3129.	2.6	24
57	Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the <i>INK4/ARF</i> locus in non-small cell lung cancer. <i>Science Signaling</i> , 2017, 10, .	5.1	24
58	Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using data-independent acquisition (DIA) mass spectrometry. <i>Prostate</i> , 2018, 78, 563-575.	2.3	24
59	The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 188-198.	0.8	24
60	Co-targeting Deoxyribonucleic Acid-Dependent Protein Kinase and Poly(Adenosine) Triphosphate Overlooked by Tumor Suppressor p53. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 385-394.	0.8	23
61	Apoptosis by p53: mechanisms, regulation, and clinical implications. <i>Seminars in Immunopathology</i> , 1998, 19, 345-362.	4.0	22
62	A quantitative model to predict pathogenicity of missense variants in the <i>TP53</i> gene. <i>Human Mutation</i> , 2019, 40, 788-800.	2.8	21
63	Ubiquitin ligase E6AP mediates nonproteolytic polyubiquitylation of β -catenin independent of the E6 oncoprotein. <i>Journal of General Virology</i> , 2016, 97, 3313-3330.	2.9	19
64	Frequent amplifications of <i>ESR1</i> , <i>ERBB2</i> and <i>MDM4</i> in primary invasive lobular breast carcinoma. <i>Cancer Letters</i> , 2019, 461, 21-30.	7.3	18
65	Hhex induces promyelocyte self-renewal and cooperates with growth factor independence to cause myeloid leukemia in mice. <i>Blood Advances</i> , 2018, 2, 347-360.	5.4	16
66	p53: An Internal Investigation. <i>Cell Cycle</i> , 2002, 1, 105-110.	2.8	15
67	E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers. <i>Carcinogenesis</i> , 2019, 40, 707-714.	2.8	15
68	P53 at the start of the 21st century: lessons from elephants. <i>F1000Research</i> , 2017, 6, 2041.	1.6	15
69	New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers. <i>Frontiers in Oncology</i> , 2013, 3, 124.	2.9	14
70	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. <i>International Journal of Cancer</i> , 2019, 144, 1151-1159.	5.4	14
71	Moloney virus induction of T-cell lymphomas in a plasmacytomagenic strain of <i>1/4-V-ABL</i> transgenic mice. <i>International Journal of Cancer</i> , 1993, 55, 623-629.	5.4	13
72	Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 1170-1183.	3.9	13

#	ARTICLE	IF	CITATIONS
73	p53 Calls upon CIA (Calcium Induced Apoptosis) to Counter Stress. <i>Frontiers in Oncology</i> , 2015, 5, 57.	2.9	12
74	Improving Cancer Therapy through p53 Management. <i>Cell Cycle</i> , 2004, 3, 910-914.	2.8	11
75	Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer. <i>Journal of Drug Targeting</i> , 2011, 19, 859-873.	4.5	11
76	E6AP Promotes a Metastatic Phenotype in Prostate Cancer. <i>IScience</i> , 2019, 22, 1-15.	4.1	11
77	Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex Disparity. <i>Frontiers in Genetics</i> , 2021, 12, 632719.	2.3	10
78	Introduction: p53 Regulationâ€”A Family Affair. <i>Cell Cycle</i> , 2004, 3, 882-883.	2.8	9
79	Biodosimetric transcriptional and proteomic changes are conserved in irradiated human tissue. <i>Radiation and Environmental Biophysics</i> , 2018, 57, 241-249.	1.4	8
80	Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status. <i>Cancers</i> , 2022, 14, 3947.	3.8	8
81	Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report. <i>BMC Urology</i> , 2020, 20, 171.	1.5	7
82	Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species. <i>Anti-Cancer Drugs</i> , 2006, 17, 609-619.	1.4	6
83	Mutant p53 subverts PLK2 function in a novel, reinforced loop of corruption. <i>Cell Cycle</i> , 2012, 11, 217-218.	2.8	6
84	Flow Cytometric Analysis of p53-Induced Apoptosis. <i>Methods in Molecular Biology</i> , 2003, 234, 245-256.	0.0	5
85	Cannibalism in Breast Cancer: The Dangers of Overeating. <i>Trends in Cancer</i> , 2019, 5, 761-762.	7.8	4
86	Restoring PML tumor suppression to combat cancer. <i>Cell Cycle</i> , 2012, 11, 3705-3706.	2.8	3
87	Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins. <i>Frontiers in Oncology</i> , 2016, 6, 170.	2.9	3
88	Establishing the Link between X-Chromosome Aberrations and TP53 Status, with Breast Cancer Patient Outcomes. <i>Cells</i> , 2023, 12, 2245.	4.3	2
89	P53 and Cell Death. , 0, , .		1
90	Corrigendum to â€”The long and the short of it: the MDM4 tail so farâ€™. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 1104-1104.	3.3	0

#	ARTICLE	IF	CITATIONS
91	The p53-Mdm2 Loop: A Critical Juncture of Stress Response. Molecular Biology Intelligence Unit, 2010, , 65-84.	0.0	0
92	New exciting possibilities for the development of precision medicine therapies to restore the expression of the INK4/ARF locus. Annals of Research Hospitals, 0, 1, 1-1.	0.0	0